Blood Reviews
Volume 23, Issue 4 , Pages 167-176 , July 2009

Disseminated intravascular coagulation in obstetric disorders and its acute haematological management

  • Jecko Thachil

      Affiliations

    • School of Clinical Sciences, University of Liverpool, Royal Liverpool University Hospital, Liverpool, UK
    • Corresponding Author InformationCorresponding author. Address: Department of Haematology, School of Clinical Sciences, University of Liverpool, 4th floor, UCD, Daulby Street, Liverpool, L69 3GA, UK.
    • ,
  • Cheng-Hock Toh

      Affiliations

    • School of Clinical Sciences, University of Liverpool, Royal Liverpool University Hospital, Liverpool, UK
    • Road Dahl Haemostasis and Thrombosis Centre, Royal Liverpool University Hospital, Liverpool, UK

References 

  1. Dutt T, Toh CH. The Yin-Yang of thrombin and activated protein C. Br J Haematol. 2008;140:505–515
  2. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8:776–787
  3. Letsky EA. Disseminated intravascular coagulation. Best Pract Res Clin Obstet Gynaecol. 2001;15:623–644
  4. Clark SL, Hankins G, Dudley DA, et al. Amniotic fluid embolism: analysis of the national registry. Am J Obstet Gynecol. 1995;172:1158–1167
  5. Davies S. Amniotic fluid embolus: a review of the literature. Can J Anaesth. 2001;48:88–98
  6. Pritchard JA. Fetal death in utero. Obstet Gynecol. 1959;14:573–580
  7. Jimenez JM, Pritchard JA. Pathogenesis and treatment of coagulation defects resulting from fetal death. Obstet Gynecol. 1968;32:449–459
  8. Petersen IR, Nyholm HC. Multiple pregnancies with single intrauterine demise. Acta Obstet Gynecol Scand. 1999;78:202–206
  9. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785–799
  10. Dekker GA. Surgically obtained sperm and risk of gestational hypertension and pre-eclampsia. Lancet. 2002;359:673–674
  11. Ishihara N, Matsuo H, Murakoshi H, et al. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol. 2002;186:158–166
  12. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180:499–506
  13. Savvidou MD, Hingorani AD, Tsikas D, et al. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 2003;361:1511–1517
  14. Redman CW. Platelets and the beginnings of preeclampsia. N Engl J Med. 1990;323:478–480
  15. Oyelese Y, Ananth CV. Placental abruption. Obstet Gynecol. 2006;108:1005–1016
  16. De Lee JB. A case of fatal hemorrhagic diathesis, with premature detachment of the placenta. Am J Obstet Dis Women Child. 1901;44:785–792
  17. Kramer MS, Usher RH, Pollack R, et al. Etiologic determinants of abruptio placentae. Obstet Gynecol. 1997;89:221–226
  18. Steinborn A, Seidl C, Sayehli C, et al. Anti-fetal immune response mechanisms may be involved in the pathogenesis of placental abruption. Clin Immunol. 2004;110:45–54
  19. Ananth CV, Getahun D, Peltier MR, et al. Placental abruption in term and preterm gestations: evidence for heterogeneity in clinical pathways. Obstet Gynecol. 2006;107:785–792
  20. Rana A, Sawhney H, Gopalan S, et al. Abruptio placentae and chorioamnionitis –microbiological and histologic correlation. Acta Obstet Gynecol Scand. 1999;78:363–366
  21. Weiner CP. The obstetric patient and disseminated intravascular coagulation. Clin Perinatol. 1986;13:705–717
  22. Hess JR. Blood and coagulation support in trauma care. Hematol Am Soc Hematol Educ Program. 2007;2007:187–191
  23. Schouten M, Wiersinga WJ, Levi M, et al. Inflammation, endothelium, and coagulation in sepsis. J Leukocyte Biol. 2008;83:536–545
  24. Martin JN, Rose CH, Briery CM. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol. 2006;195:914–934
  25. Fang CJ, Richards A, Liszewski MK, et al. Advances in understanding of pathogenesis of aHUS and HELLP. Br J Haematol. 2008;143:336–348
  26. Bacq Y. Acute fatty liver of pregnancy. Semin Perinatol. 1998;22:134–140
  27. Castro MA, Goodwin MT, Shaw KJ, et al. Disseminated intravascular coagulation and antithrombin III depression in acute fatty liver of pregnancy. Am J Obstet Gynecol. 1996;174:211–216
  28. Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am. 2007;21:1–11
  29. Oliver J, Monroe D, Roberts H, et al. Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol 1999;19:170–7.
  30. Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem. 1982;257:7944–7947
  31. Pérez-Casal M, Downey C, Fukudome K, et al. Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood. 2005;105:1515–1522
  32. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269:31869–31880
  33. Bajaj MS, Birktoft JJ, Steer SA, et al. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost. 2001;86:959–972
  34. Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost. 2003;89:409–419
  35. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin–thrombomodulin complex. J Biol Chem. 1996;271:16603–16608
  36. Nesheim ME, Tracy RP, Mann KG. ‘Clotspeed’, a mathematical simulation of the functional properties of prothrombinase. J Biol Chem. 1984;259:1447–1453
  37. Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine–phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol. 1988;69:491–497
  38. Giles AR, Nesheim ME, Mann KG. Studies of factors V and VIII:C in an animal model of disseminated intravascular coagulation. J Clin Invest. 1984;74:2219–2225
  39. Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem. 1994;269:816–819
  40. Rosing J, van Rijn JL, Bevers EM, et al. The role of activated human platelets in prothrombin and factor X activation. Blood. 1985;65:319–332
  41. Moyer MP, Tracy RP, Tracy PB, et al. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol. 1998;18:458–465
  42. Bretelle F, Sabatier F, Desprez D, et al. Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost. 2003;89:486–492
  43. Cabana VG, Siegel JN, Sabesin SM. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res. 1989;30:39–49
  44. Dennis MW, Downey C, Brufatto N, et al. Prothrombinase enhancement through quantitative and qualitative changes affecting very low density lipoprotein in complex with C-reactive protein. Thromb Haemost. 2004;9:522–530
  45. Griffin JH, Kojima K, Banka CL, et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest. 1999;103:219–227
  46. Sattar N, Bendomir A, Berry C, et al. Lipoprotein subfraction concentrations in preeclampsia: pathogenic parallels to atherosclerosis. Obstet Gynecol. 1997;89:403–408
  47. Reverdiau P, Jarousseau AC, Thibault G, et al. Tissue factor activity of syncytiotrophoblast plasma membranes and tumoral trophoblast cells in culture. Thromb Haemost. 1995;73:49–54
  48. Aharon A, Brenner B, Katz T, et al. Tissue factor and tissue factor pathway inhibitor levels in trophoblast cells: implications for placental hemostasis. Thromb Haemost. 2004;92:776–786
  49. Pedersen B, Holscher T, Sato Y, et al. A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice. Blood. 2005;105:2777–2782
  50. Brenner B. Haemostatic changes in pregnancy. Thromb Res. 2004;114:409–414
  51. Boffa MC, Valsecchi L, Fausto A, et al. Predictive value of plasma thrombomodulin in preeclampsia and gestational hypertension. Thromb Haemost. 1998;79:1092–1095
  52. Isermann B, Sood R, Pawlinski R, et al. The thrombomodulin–protein C system is essential for the maintenance of pregnancy. Nat Med 2003;9:331–7.
  53. Gu JM, Crawley JT, Ferrell G, et al. Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J Biol Chem. 2002;277:43335–43343
  54. Hurtado V, Montes R, Gris JC, et al. Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for foetal death. Blood. 2004;104:1369–1374
  55. Clark P, Brennand J, Conkie JA, et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost. 1998;79:1166–1170
  56. Comp PC, Thurnau GR, Welsh J, et al. Functional and immunologic protein S levels are decreased during pregnancy. Blood. 1986;68:881–885
  57. Cumming AM, Tait RC, Fildes S, et al. Development of resistance to activated protein C during pregnancy. Br J Haematol. 1995;90:725–727
  58. Bremme K, Ostlund E, Almqvist I, et al. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet Gynecol. 1992;80:132–137
  59. Cerneca F, Ricci G, Simeone R, et al. Coagulation and fibrinolysis changes in normal pregnancy. Eur J Obstet Gynecol Reprod Biol. 1997;73:31–36
  60. van Wersch JW, Ubachs JM. Blood coagulation and fibrinolysis during normal pregnancy. Eur J Clin Chem Clin Biochem. 1991;29:45–50
  61. Robb AO, Mills NL, Din JN, et al. Acute endothelial tissue plasminogen activator release in pregnancy. J Thromb Haemost. 2009;7:138–142
  62. Toh CH. Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction. Blood Coagul Fibrin. 2003;14(Suppl 1):S69–S71
  63. Chabloz P, Reber G, Boehlen F, et al. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol. 2001;115:150–152
  64. Mousa HA, Downey C, Alfirevic Z, et al. Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy. Thromb Haemost. 2004;92:1025–1031
  65. Das M, Xu B, Lin L, et al. Phosphatidylserine efflux and intercellular fusion in a BeWo model of human villous cytotrophoblast. Placenta. 2004;25:396–407
  66. Katsuragawa H, Rote NS, Inoue T, et al. Monoclonal antiphosphatidylserine antibody reactivity against human first-trimester placental trophoblasts. Am J Obstet Gynecol. 1995;172:1592–1597
  67. O’Riordan MN, Higgins JR. Haemostasis in normal and abnormal pregnancy. Best Pract Res Clin Obstet Gynaecol. 2003;17:385–396
  68. Wallenburg HC, van Kessel PH. Platelet lifespan in normal pregnancy as determined by a non-radioisotopic technique. BJOG. 1978;85:33–36
  69. Neame PB, Kelton JG, Walker IR, et al. Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation. Blood. 1980;56:88–92
  70. Levi M, ten Cate H, van der Poll T. Disseminated intravascular coagulation: state of the art. Thromb Haemost. 1999;82:695–705
  71. Manten GT, Franx A, Sikkema JM, et al. Fibrinogen and high molecular weight fibrinogen during and after normal pregnancy. Thromb Res. 2004;114:19–23
  72. Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost. 2007;5:266–273
  73. Nieuwenhuizen W. A reference material for harmonisation of D-dimer assays. Thromb Haemost. 1997;77:1031–1033
  74. Taylor FB, Toh CH, Hoots K, et al. Towards a definition, clinical and laboratory criteria and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1027–1030
  75. Toh CH, Hoots WK. The scoring system of the SSC on DIC of the ISTH: a 5-year overview. J Thromb Haemost. 2007;5:604–606
  76. Boisclair MD, Ireland H, Lane DA. Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Rev. 1990;4:25–40
  77. Cadroy Y, Grandjean H, Pichon J, et al. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol. 1993;100:416–420
  78. Halligan A, Bonnar J, Sheppard B, et al. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br J Obstet Gynaecol. 1994;101:488–492
  79. Weiner CP. The mechanism of reduced antithrombin III activity in women with preeclampsia. Obstet Gynecol. 1988;72:847–849
  80. Magriples U, Chan DW, Bruzek D, et al. Thrombomodulin: a new marker for placental abruption. Thromb Haemost. 1999;81:32–34
  81. Franchi F, Biguzzi E, Cetin I, et al. Mutations in the thrombomodulin and endothelial protein C receptor genes in women with late fetal loss. Br J Haematol. 2001;114:641–646
  82. Kaare M, Ulander VM, Painter JN, et al. Variations in the thrombomodulin and endothelial protein C receptor genes in couples with recurrent miscarriage. Hum Reprod. 2007;22:864–868
  83. Estellés A, Gilabert J, Grancha S, et al. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. Thromb Haemost. 1998;79:500–508
  84. Chappell LC, Seed PT, Briley A, et al. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol. 2002;187:127–136
  85. Antovic JP, Rafik Hamad R, et al. Does thrombin activatable fibrinolysis inhibitor contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?. Thromb Haemost. 2002;88:644–647
  86. He S, Bremme K, Blombäck M. A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results. Thromb Res. 1999;96:145–156
  87. VanWijk MJ, Nieuwland R, Boer K. Microparticle subpopulations are increased in preeclampsia: possible involvement in vascular dysfunction?. Am J Obstet Gynecol. 2002;187:450–456
  88. Redman CW, Sargent IL. Circulating microparticles in normal pregnancy and pre-eclampsia. Placenta. 2008;29(Suppl. A):S73–S77
  89. Higgins JR, Walshe JJ, Darling MR, et al. Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies. Am J Obstet Gynecol. 1998;179:520–526
  90. Josic D, Hoffer L, Buchacher A, et al. Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity. Thromb Res. 2000;100:433–441
  91. Preston FE, Laidlaw ST, Sampson B, et al. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol. 2002;116:619–624
  92. Kreuz W, Meili E, Peter-Salonen K, et al. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apher Sci. 2005;32:247–253
  93. Haas T, Fries D, Velik-Salchner C, et al. Fibrinogen in craniosynostosis surgery. Anesth Analg. 2008;106:725–731
  94. Weinkove R, Rangarajan S. Fibrinogen concentrate for acquired hypofibrinogenaemic states. Transfus Med. 2008;18:151–157
  95. Corrigan JJ, Jordan CM. Heparin therapy in septicemia with disseminated intravascular coagulation. N Engl J Med. 1970;283:778–782
  96. Feinstein DI. Treatment of disseminated intravascular coagulation. Semin Thromb Hemost. 1988;14:351–362
  97. Kobayashi T, Terao T, Ikenoue T, et al. BI51017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Semin Thromb Hemost. 2003;29:645–652
  98. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709
  99. Kobayashi T, Terao T, Maki M, et al. Activated protein C is effective for disseminated intravascular coagulation associated with placental abruption. Thromb Haemost 1999;82:1363.
  100. Wise A, Clark V. Strategies to manage major obstetric haemorrhage. Curr Opin Anaesthesiol. 2008;21:281–287
  101. Jansen AJ, van Rhenen DJ, Steegers EA, et al. Postpartum hemorrhage and transfusion of blood and blood components. Obstet Gynecol Surv. 2005;60:663–671
  102. Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ. BCSH guidelines on the management of massive blood loss. Br J Haematol. 2006;135:634–641
  103. Van der Linden P, Ickx BE. The effects of colloid solutions on hemostasis. Can J Anaesth. 2006;53(Suppl. 6):S30–S39
  104. Hirshberg A, Dugas M, Banez E, Scott B, Wall M, Mattox K. Minimizing dilutional coagulopathy in exanguinating hemorrhage: a computer simulation. J Trauma. 2003;54:454–461
  105. Malone DL, Hess JR, Fingerhut A. Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. J Trauma. 2006;60(Suppl. 6):S91–S96
  106. Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma. 2007;63:805–813
  107. Johansson PI, Stensballe J, Rosenberg I, et al. Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: evaluating a change in transfusion practice. Transfusion. 2007;47:593–598
  108. Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, et al. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth. 2008;101:769–773
  109. Meng ZH, Wolberg AS, Monroe DM, et al. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma. 2003;55:886–891
  110. Gabriel A, Li X, Monroe DM, et al. Recombinant human factor VIIa, (rFVIIa) can activate FX on activated platelets. J Thromb Haemost. 2004;2:1816–1822
  111. Sobieszczyk S, Breborowicz GH, Platicanov V, et al. Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical use. Acta Obstet Gynecol Scand. 2006;85:1239–1247
  112. Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. Br J Obstet Gynaecol. 2007;114:8–15
  113. Haynes J, Laffan M, Plaat F. Use of recombinant activated factor VII in massive obstetric haemorrhage. Int J Obstet Anesth. 2007;16:40–49
  114. Payne EM, Brett SJ, Laffan MA. Efficacy of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: a single centre experience. Blood Coagul Fibrin. 2006;17:397–402
  115. Searle E, Pavord S, Alfirevic Z. Recombinant factor VIIa and other pro-haemostatic therapies in primary postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol. 2008;22:1075–1088

PII: S0268-960X(09)00028-9

doi: 10.1016/j.blre.2009.04.002

Blood Reviews
Volume 23, Issue 4 , Pages 167-176 , July 2009

Article Tools

* Image Usage & Resolution